Mark McPartland

Business development, corporate communications and capital markets advisory consultant. Early to rise - quick to listen - slow to speak - slower to anger!

[Mark McPartland @markmcp]

“The completion of the PALISADE-3 Phase 3 public speaking challenge study marks an important milestone for Vistagen,” said Shawn Singh, President and Chief Executive Officer. https://t.co/6L6Vblkr5P

[Mark McPartland @markmcp]

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder - https://t.co/6L6Vblkr5P

[Mark McPartland @markmcp]

The Business of Mental Health with Shawn Singh via @justmoneynews https://t.co/ZEJhvvUly4

[Vistagen @Vistagen]

Our CEO spoke with @PharmaVoice on the unique potential of our novel pherine nasal spray, fasedienol, for #socialanxiety disorder and the ongoing PALISADE-3 Ph 3 Study.

Read more on fasedienol's potential to be the first on-demand treatment for SAD https://t.co/IcS5sRWreg $VTGN

[Mark McPartland @markmcp]

https://t.co/OP4jlzFRkP

[Vistagen @Vistagen]

Existing #anxiety and #depression medications leave many people without a treatment that works—or a treatment that works with side effects that don’t. Our investigational nasal sprays, with potentially fewer side effects, have the potential to change that. https://t.co/lWDsLvuD1c

[Vistagen @Vistagen]

6,000 people a day enter #menopause in the U.S. but six in every 10 women are left untreated. We are developing PH80 to improve the treatment paradigm for #HotFlashes & reduce the physical burden on quality of life experienced by women worldwide. $VTGN https://t.co/4NbsCOneVR

[Mark McPartland @markmcp]

Vistagen Getting 'Back On Offense’ After US FDA Okays Endpoint For Its Social Anxiety Drug https://t.co/Ww9DSPzKVq

[Mark McPartland @markmcp]

America’s mental health crisis: Why we need a Moonshot https://t.co/vWLj0MeOwX

[Mark McPartland @markmcp]

Vistagen reports favorable results from trial of MDD therapy
https://t.co/JFcKItPDiU via @TrialsArena

[Mark McPartland @markmcp]

Revolutionizing Mental Health Treatment: VistaGen Therapeutics' Nasal Sp... https://t.co/knIKwkeZVD via @YouTube

[Vistagen @Vistagen]

CEO Shawn Singh spoke to @molecule2markt’s @ramanelli about the #MentalHealth epidemic and the potential of our pipeline medications to transform the treatment landscape for people living with CNS disorders.
https://t.co/BBa3CMYxlU
#InnovatingMentalHealth

[Mark McPartland @markmcp]

As Vistagen strives to develop transformative medicines for patients suffering from anxiety, depression and other mental health disorders, we prioritize supporting our employees’ mental health and well-being, both inside and outside of our workplace. https://t.co/CvCVsAmJd9

[Mark McPartland @markmcp]

https://t.co/ewt87pdAsW

[Mark McPartland @markmcp]

Great daily calendar to kick off Mental Health Month!

[Mental Health America @MentalHealthAm]

Looking for creative ways to stay engaged throughout #MentalHealthMonth? 🗓 Check out our printable calendar filled with ideas to make the world around you work for your #mentalhealth—just one of many resources you can find at https://t.co/oHqSbasYB0.

[Mental Health America @MentalHealthAm]

It’s officially #MentalHealthMonth! We invite you to #LookAroundLookWithin as we shine a light on how our surroundings can impact #mentalhealth. 🧠

There are so many ways to raise awareness and get involved. Learn more: https://t.co/oHqSbasYB0

[Mark McPartland @markmcp]

Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference - https://t.co/leplMLUVtS

[Vistagen @Vistagen]

Tomorrow at 12:50 PM ET, Vistagen CEO Shawn Singh will give a presentation during the @TDCowen Health Care Conference. For details, visit: https://t.co/mfrNLHNFo0 $VTGN #CowenHealthCare

[Mark McPartland @markmcp]

A great episode of Talking Biotech with Dr. Kevin Folta and Shawn Singh @Vistagen discusses Treating Mental Illness through Nasal Drug Delivery - Listen along here: https://t.co/3uZm9UW8o7

[Mark McPartland @markmcp]

“The initiation of this U.S. Phase 1 study of Vistagen’s novel pherine nasal spray, PH10, represents a major milestone for our team as well as for the millions of individuals left struggling with major depressive disorder." https://t.co/hAhmNlmXS9